[Form 4] Replimune Group, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Replimune Group, Inc. director Weinand Dieter received a grant of stock options covering 44,500 shares of common stock. The options have an exercise price of $7.61 per share and expire on April 1, 2036.

According to the filing, these options vest in full on April 1, 2027. Following this grant, Dieter holds 44,500 derivative securities directly, reflecting a compensation award rather than an open-market purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Weinand Dieter

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	44,500	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 44,500 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 44,500 shares Exercise price: $7.61 per share Expiration date: April 1, 2036 +2 more

5 metrics

Option grant size 44,500 shares Stock Option grant reported for director Weinand Dieter

Exercise price $7.61 per share Conversion or exercise price of granted stock options

Expiration date April 1, 2036 Option expiration for the 44,500-share grant

Vesting date April 1, 2027 All shares underlying this option vest entirely on this date

Holdings after grant 44,500 derivative securities Total derivative position directly held following the transaction

Key Terms

Stock Option (right to buy), exercise price, expiration date, vest

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "7.6100""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-04-01T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest financial

"The shares underlying this option vest entirely on April 1, 2027."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weinand Dieter

(Last) (First) (Middle)

C/O REPLIMUNE GROUP, INC.

500 UNICORN PARK DRIVE, SUITE 303

(Street)

WOBURN MASSACHUSETTS 01801

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Replimune Group, Inc. [ REPL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.61	04/01/2026		A		44,500		(1)	04/01/2036	Common Stock	44,500	$0	44,500	D

Explanation of Responses:

1. The shares underlying this option vest entirely on April 1, 2027.

Remarks:

This Form 4 is being filed late due to inadvertent administrative error.

	/s/ Shawn Glidden, attorney-in-fact	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Replimune (REPL) director Weinand Dieter report in this Form 4?

Replimune director Weinand Dieter reported receiving a grant of stock options for 44,500 shares. These options are a compensation award, not an open-market share purchase, and give him the right to buy Replimune common stock at a preset price.

How many Replimune (REPL) shares are covered by Dieter’s new stock options?

The new stock option grant covers 44,500 shares of Replimune common stock. This means he can choose to buy up to 44,500 shares at the fixed exercise price once the options are vested and exercisable, subject to the plan’s terms.

What is the exercise price of Weinand Dieter’s Replimune (REPL) stock options?

The exercise price of the stock options granted to Weinand Dieter is $7.61 per share. This is the fixed price he would pay to purchase Replimune common shares if he exercises the options after they vest, regardless of future market prices.

When do Weinand Dieter’s Replimune (REPL) stock options vest and expire?

All shares underlying the option vest on April 1, 2027, according to the filing footnote. The options have an expiration date of April 1, 2036, giving a long window after vesting during which they may be exercised under the plan.

Is the Replimune (REPL) Form 4 an insider share purchase in the market?

No, the Form 4 reflects a grant of stock options as compensation, not an open-market share purchase. The transaction code is “A” for grant or award, and the transaction price is reported as $0.00 because no cash was paid to receive the options.